Mark D. Wittman - Wallingford CT, US Harold Mastalerz - Guilford CT, US Kurt Zimmermann - Durham CT, US Mark G. Saulnier - Newington CT, US Upender Velaparthi - Cheshire CT, US Dolatrai M. Vyas - Madison CT, US Guifen Zhang - Wallingford CT, US Walter Lewis Johnson - Waterbury CT, US David B. Frennesson - Naugatuck CT, US Xiaopeng Sang - Glastonbury CT, US Peiying Liu - Madison CT, US David R. Langley - Meriden CT, US
The invention provides compounds of formula IThe formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.
Carol Bachand - Candiac, CA Makonen Belema - North Haven CT, US Daniel H. Deon - Brossard, CA Andrew C. Good - Wallingford CT, US Jason Goodrich - Meriden CT, US Clint A. James - Longueuil, CA Rico Lavoie - Candiac, CA Omar D. Lopez - Wallingford CT, US Alain Martel - Delson, CA Nicholas A. Meanwell - East Hampton CT, US Van N. Nguyen - New Britain CT, US Jeffrey Lee Romine - Meriden CT, US Edward H. Ruediger - Greenfield Park, CA Lawrence B. Snyder - Killingworth CT, US Denis R. St. Laurent - Newington CT, US Fukang Yang - Madison CT, US David R. Langley - Meriden CT, US Lawrence G. Hamann - North Grafton MA, US
The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
Carol Bachand - Candiac, CA Makonen Belema - North Haven CT, US Daniel H. Deon - Brossard, CA Andrew C. Good - Wallingford CT, US Jason Goodrich - Meriden CT, US Clint A. James - Longueuil, CA Rico Lavoie - Candiac, CA Omar D. Lopez - Wallingford CT, US Alain Martel - Delson, CA Nicholas A. Meanwell - East Hampton CT, US Van N. Nguyen - Meriden CT, US Jeffrey Lee Romine - Meriden CT, US Edward H. Ruediger - Greenfield Park, CA Lawrence B. Snyder - Killingworth CT, US Denis R. St. Laurent - Newington CT, US Fukang Yang - Madison CT, US David R. Langley - Meriden CT, US Gan Wang - Wallingford CT, US Lawrence G. Hamann - North Grafton MA, US
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
A61K 31/55 A61K 31/4155 C07D 223/18 C07D 233/54
US Classification:
514217, 514397, 540587, 5483114, 5483131
Abstract:
The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
Carol Bachand - Candiac, CA Makonen Belema - North Haven CT, US Daniel H. Deon - Brossard, CA Andrew C. Good - Wallingford CT, US Jason Goodrich - Meriden CT, US Lawrence G. Hamann - North Grafton MA, US Clint A. James - Longueuil, CA David R. Langley - Meriden CT, US Rico Lavoie - Candiac, CA Omar D. Lopez - Wallingford CT, US Alain Martel - Delson, CA Nicholas A. Meanwell - East Hampton CT, US Van N. Nguyen - Meriden CT, US Jeffrey Lee Romine - Meriden CT, US Edward H. Ruediger - Greenfield Park, CA Lawrence B. Snyder - Killingworth CT, US Denis R. St. Laurent - Newington CT, US Gan Wang - Wallingford CT, US Fukang Yang - Madison CT, US
The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
Carol Bachand - Candiac, CA Makonen Belema - North Haven CT, US Daniel H. Deon - Brossard, CA Andrew C. Good - Wallingford CT, US Jason Goodrich - Meriden CT, US Clint A. James - Longueuil, CA Rico Lavoie - Candiac, CA Omar D. Lopez - Wallingford CT, US Alain Martel - Delson, CA Nicholas A. Meanwell - East Hampton CT, US Van N. Nguyen - Meriden CT, US Jeffrey Lee Romine - Meriden CT, US Edward H. Ruediger - Greenfield Park, CA Lawrence B. Snyder - Killingworth CT, US Denis R. St. Laurent - Newington CT, US Fukang Yang - Madison CT, US David R. Langley - Meriden CT, US Gan Wang - Wallingford CT, US Lawrence G. Hamann - North Grafton MA, US
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
C07D 233/02 A01N 43/50
US Classification:
5483001, 514396
Abstract:
The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
Carol Bachand - Candiac, CA Makonen Belema - North Haven CT, US Daniel H. Deon - Brossard, CA Andrew C. Good - Wallingford CT, US Jason Goodrich - Meriden CT, US Clint A. James - Longueuil, CA Rico Lavoie - Candiac, CA Omar D. Lopez - Wallingford CT, US Alain Martel - Delson, CA Nicholas A. Meanwell - East Hampton CT, US Van N. Nguyen - New Britain CT, US Jeffrey Lee Romine - Meriden CT, US Edward H. Ruediger - Greenfield Park, CA Lawrence B. Snyder - Killingworth CT, US Denis R. St. Laurent - Newington CT, US Fukang Yang - Madison CT, US David R. Langley - Meriden CT, US Lawrence G. Hamann - North Grafton MA, US
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
C07D 233/02 A01N 43/50
US Classification:
5483001, 514396
Abstract:
The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
Mark D. Wittman - Wallingford CT, US Harold Mastalerz - Guilford CT, US Kurt Zimmermann - Durham CT, US Mark G. Saulnier - Newington CT, US Upender Velaparthi - Cheshire CT, US Dolatrai M. Vyas - Madison CT, US Guifen Zhang - Wallingford CT, US Walter Lewis Johnson - Waterbury CT, US David B. Frennesson - Naugatuck CT, US Xiaopeng Sang - Glastonbury CT, US Peiying Liu - Madison CT, US David R. Langley - Meriden CT, US
The invention provides compounds of formula IThe formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.
Carol Bachand - Candiac, CA Makonen Belema - North Haven CT, US Daniel H. Deon - Brossard, CA Andrew C. Good - Wallingford CT, US Jason Goodrich - Meriden CT, US Clint A. James - Longueuil, CA Rico Lavoie - Candiac, CA Omar D. Lopez - Wallingford CT, US Alain Martel - Delson, CA Nicholas A. Meanwell - East Hampton CT, US Van N. Nguyen - Meriden CT, US Jeffrey Lee Romine - Meriden CT, US Edward H. Ruediger - Greenfield Park, CA Lawrence B. Snyder - Killingworth CT, US Denis R. St. Laurent - Newington CT, US Fukang Yang - Madison CT, US David R. Langley - Meriden CT, US Gan Wang - Wallingford CT, US Lawrence G. Hamann - North Grafton MA, US
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
A61K 31/535 C07D 413/00
US Classification:
5142345, 544119
Abstract:
The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
Natures Garden Delivered Atlanta, GA Sep 2013 to Feb 2015 DriverPop Tab Photos Atlanta, GA Sep 2012 to Sep 2013 Event CoordinatorImagine One Hanahan, SC Jan 2010 to Sep 2012 Technical Writer
Education:
University of West Georgia Dec 2009 B.A. in English
Dr. Langley graduated from the Baylor College of Medicine in 1998. He works in Amarillo, TX and specializes in General Surgery and Vascular Surgery. Dr. Langley is affiliated with BSA Hospital.
The defendant concealed his interest in said assets by failing to disclose these assets in any filings with the court, said the December filing by Alicia Duersons lawyer, David Langley. Langley declined to comment.
Arlington, VAEditor & Principal at Pictures & Players Past: Avid Symphony Editor at Waveworks Digital Media, Broadcast Editor at Admine.com, Editor at...